# Shattuck Labs to Participate in Upcoming December Investor Conferences
Canonical URL: https://biopharmsignal.com/news/STTK/shattuck-labs-to-participate-in-upcoming-december-investor-conferences-429bf68f
Ticker: STTK
Company: Shattuck Labs
Source: Shattuck Labs
Published: 2025-11-20 13:00 EST
## Summary

AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage...

## Article Body
AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that Company management will participate in multiple investor conferences in December 2025.

Conference Details

Conference: Piper Sandler 37 th Annual Healthcare Conference Format: Presentation and one-on-one meetings Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer Presentation Date: Dec 2, 2025 Time: 10:10 AM EST Location: New York, NY Webcast link: HERE

Conference: Evercore ISI 8 th Annual HealthCONx Conference Format: Fireside chat with Umer Raffat and Jonathan Miller, Ph.D. and one-on-one meetings (Dec 3-4) Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer Fireside Chat Date: Dec 4, 2025 Time: 8:20 AM EST Location: Coral Gables, FL Webcast link: HERE

A replay of the presentations from the Piper Sandler 37 th Annual Healthcare Conference and the Evercore ISI 8 th Annual HealthCONx Conference will be available on the Events and Presentations section of the Company’s website. A replay of the webcasts will remain archived for up to 30 days following the presentation date.

About SL-325

SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 is a fully Fc-silenced humanized immunoglobin G monoclonal antibody with a favorable safety profile in non-human primates, currently being evaluated in a Phase 1 clinical trial.

About Shattuck Labs, Inc. Shattuck Labs, Inc. (Nasdaq: STTK) is a clinical-stage biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor & Media Contact: Andrew R. Neill Chief Financial Officer Shattuck Labs, Inc. InvestorRelations@shattucklabs.com
## Recent Company News
- 2026-06-10 04:21 EST — [Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering](https://biopharmsignal.com/news/STTK/shattuck-labs-inc-announces-pricing-of-75-million-public-offering-1147ed04) — Source: Shattuck Labs
- 2026-06-09 20:18 EST — [Shattuck Labs, Inc. Announces Proposed Public Offering](https://biopharmsignal.com/news/STTK/shattuck-labs-inc-announces-proposed-public-offering-81c3c0e1) — Source: Shattuck Labs
- 2026-06-09 12:00 EST — [Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update](https://biopharmsignal.com/news/STTK/shattuck-labs-announces-exercise-of-outstanding-common-stock-warrants-and-provid-5897ec16) — Source: Shattuck Labs
- 2026-06-08 10:00 EST — [Shattuck Labs Announces Phase 1 Results for SL-325](https://biopharmsignal.com/news/STTK/shattuck-labs-announces-phase-1-results-for-sl-325-e7f7caf7) — Source: Shattuck Labs
- 2026-06-05 20:05 EST — [Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8](https://biopharmsignal.com/news/STTK/shattuck-labs-to-host-investor-call-and-webcast-on-phase-1-clinical-data-of-sl-3-d25fd1ba) — Source: Shattuck Labs
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)